Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (...
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2019
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_61518 | ||
| 005 | 20210212 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210212s2019 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-03921-316-0 | ||
| 020 | |a 9783039213160 | ||
| 020 | |a 9783039213153 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-03921-316-0 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a PS |2 bicssc | |
| 100 | 1 | |a Contel, Maria |4 auth | |
| 245 | 1 | 0 | |a Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2019 | ||
| 300 | |a 1 electronic resource (204 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 653 | |a ?-? stacking | ||
| 653 | |a encapsulation | ||
| 653 | |a n/a | ||
| 653 | |a oxindolimine-metal complexes | ||
| 653 | |a cyclodextrin | ||
| 653 | |a platinum iodido complexes | ||
| 653 | |a distribution coefficient | ||
| 653 | |a antiproliferative activity | ||
| 653 | |a anticancer agents | ||
| 653 | |a nanotubes | ||
| 653 | |a ruthenium | ||
| 653 | |a platinum | ||
| 653 | |a Log kw | ||
| 653 | |a nanoparticles | ||
| 653 | |a drug discovery | ||
| 653 | |a metal complex | ||
| 653 | |a metallodrugs | ||
| 653 | |a isatin-derived ligands | ||
| 653 | |a anticancer drug | ||
| 653 | |a upconverting nanoparticles | ||
| 653 | |a pyridine benzimidazole | ||
| 653 | |a dendrimers | ||
| 653 | |a liposomes | ||
| 653 | |a thiophene | ||
| 653 | |a angiogenesis | ||
| 653 | |a micelles | ||
| 653 | |a HSA oxidation | ||
| 653 | |a platinum(IV) | ||
| 653 | |a imaging | ||
| 653 | |a chromatographic lipophilicity parameter | ||
| 653 | |a amidophosphine | ||
| 653 | |a copper and iron chelators in cancer | ||
| 653 | |a Log P | ||
| 653 | |a biomacromolecules | ||
| 653 | |a bones | ||
| 653 | |a DNA cleavage | ||
| 653 | |a stopped-flow spectroscopy | ||
| 653 | |a silver | ||
| 653 | |a phosphonates | ||
| 653 | |a transmetalation | ||
| 653 | |a metallomics | ||
| 653 | |a MRI | ||
| 653 | |a fluorescence quenching | ||
| 653 | |a partition coefficient | ||
| 653 | |a gold fingers | ||
| 653 | |a anticancer | ||
| 653 | |a HSA binding | ||
| 653 | |a gold | ||
| 653 | |a ?0 | ||
| 653 | |a targeting | ||
| 653 | |a metastasis | ||
| 653 | |a DNA interaction | ||
| 653 | |a antimigration | ||
| 653 | |a cytotoxicity | ||
| 653 | |a HPLC | ||
| 653 | |a ruthenium complexes | ||
| 653 | |a zinc finger proteins | ||
| 653 | |a Gold(III) complexes | ||
| 653 | |a aquaporins | ||
| 653 | |a antiproliferative | ||
| 653 | |a protein-DNA recognition | ||
| 653 | |a photoactivation | ||
| 653 | |a lipophilicity | ||
| 653 | |a cancer | ||
| 653 | |a 1-methylcytosine | ||
| 653 | |a PET | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/1637 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/61518 |7 0 |z DOAB: description of the publication |